Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Ruxolitinib is a potent and selective JAK1/2 inhibitor (IC50 values are 3.3 and 2.8 nM, respectively). Exhibits selectivity for JAK1/2 over Tyk2 and JAK3 (~6-fold and >130-fold, respectively). Exhibits no significant inhibition against a commercial panel of 26 additional kinases. Inhibits JAK2V617F-mediated signaling and proliferation in Ba/F3 cells and HEL cells. Increases survival rates in a JAK2V617F-driven myeloproliferative neoplasm mouse model. Ruxolitinib has been identified as targeting human host proteins that interact with SARS-CoV-2. The compound can also be used in protocols for the chemical reprogramming of somatic cells to iPSCs. Orally bioavailable.
Phosphate salt (Cat. No. 7048) also available.
Ruxolitinib is also offered as part of the Tocriscreen 2.0 Max, Tocriscreen Kinase Inhibitor Library, Tocriscreen Antiviral Library, Tocriscreen Epigenetics Library and Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 306.37. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.26 mL||16.32 mL||32.64 mL|
|5 mM||0.65 mL||3.26 mL||6.53 mL|
|10 mM||0.33 mL||1.63 mL||3.26 mL|
|50 mM||0.07 mL||0.33 mL||0.65 mL|
References are publications that support the biological activity of the product.
Lin et al (2009) Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction. Org.Lett. 11 1999 PMID: 19385672
Quintás-Cardama et al (2010) Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115 3109 PMID: 20130243
Gordon et al (2020) A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing. Nature 583 PMID: 32353859
Guan et al (2022) Chemical reprogramming of human somatic cells to pluripotent stem cells Nature 605 325 PMID: 35418683
If you know of a relevant reference for Ruxolitinib, please let us know.
Keywords: Ruxolitinib, Ruxolitinib supplier, Potent, selective, JAK1/JAK2, inhibitors, inhibits, JAK1, JAK2, orally, bioavailable, active, in, vivo, COVID-19, SARS-CoV-2, severe, acute, respiratory, syndrome, induced, pluripotent, stem, cells, reprogramming, iPSC, INCB018424, JAK, Kinase, Coronavirus, Stem, Cell, Reprogramming, 7064, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Ruxolitinib. Do you know of a great paper that uses Ruxolitinib from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Ruxolitinib and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.